NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript February 22, 2024 NovoCure Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this […]
Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million
PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug.